Human African trypanosomiasis

Pepin, J., and F. Milford. "The Treatment of Human African Trypanosomiasis." Advances in Parasitology 33 (1994) 2-47. [Pg.236]

Belete, H., Tikubet, G., Petros, B., Oyibu, W. A., and Otigbuo, I. N. (2004). Control of human African trypanosomiasis trap and odour preference of tsetse flies (Glossina morsitans submorsitans) in the upper Didessa River Valley of Ethiopia. Tropical Medicine and International Health 9,710-714. [Pg.434]

Legros D et al Treatment of human African trypanosomiasis—present situation and needs for research and development. Lancet Infect Dis 2002 2 437. [PMID 12127356]... [Pg.1144]

Schmid C et al Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis Confirmation from a multinational study (IMPAMEL II). J Infect Dis 2005 191 1922. [PMID 15871127]... [Pg.1144]

Available drugs for the treatment of human African trypanosomiasis. [Pg.366]

Human African trypanosomiasis (African sleeping sickness) around 60 million people at risk In sub-Saharan Africa, resulting annually in around 500,000 cases and 50,000 deaths. Fatal if not treated. Most drugs are old and difficult to administer. Until recently the only treatment available for the second-stage of the disease was Melarsoprol, an arsenic-based drug that kills 5 per cent of patients. [Pg.112]

Key words Trypanosoma brucei, RNA-editing ligase 1, REL1, Human African trypanosomiasis, African sleeping sickness, TbRELl, Editosome... [Pg.231]

Bouteille B, Oukem O, Bisser S et al (2003) Treatment perspectives for human African trypanosomiasis. Fundam Clin Pharmacol 17 171-181... [Pg.16]

Friedheim EAH (1948) Melarsen oxide in the treatment of human African trypanosomiasis. Ann Trop Med 42 357-363... [Pg.17]

Kennedy PGE (2006) Diagnostic and neuropathogenesis issues in human African trypanosomiasis. Int J Parasitol 36 505-512... [Pg.18]

Adams JH, Haller L, Boa FY et al (1986) Human African trypanosomiasis (T.b. gambiense) a study of 16 fatal cases of sleeping sickness with some observations on acute reactive arsenical encephalopathy. Neuropathol Appl Neurobiol 12 81-94... [Pg.18]

Kennedy PGE (2008) The continuing problem of human African trypanosomiasis (sleeping sickness). Ann Neurol 64 116-126... [Pg.18]

The African Region is the WHO Region with the highest burden of tropical diseases. It is estimated that 80-90% of total clinical malaria cases (300-500 million) and malaria-related deaths (1.5-2.7 million) occur in Africa and about 55 million people are at risk of human African trypanosomiasis. Plague remains a public health problem in several countries, with around 1000 cases and 100 deaths yearly, and several countries in Central and Eastern Africa experience a high prevalence of onchocerciasis. Schistosomiasis and relapsing fever also add to the burden of tropical diseases, although they are endemic in more limited areas. [Pg.5]

Activities to control the vectors of schistosomiasis and human African trypanosomiasis remain limited but will be intensified in the future, particularly for tsetse fly control, for which insecticide-treated traps and screens represent the main method. [Pg.6]

Encephalopathic syndromes complicating treatment of stage II human African trypanosomiasis with melarsoprol in 588 patients have been reviewed (8). The overall rate of encephalopathy was 5.8% and presented in three ways coma, convulsions, and psychotic reactions. The overall death rate was 38%. Comatose patients had a death rate of 52% and were commonly co-infected with malaria (14/16). Symptoms during treatment of fever (RR = 11.5), headache (RR = 2.5), bullous eruptions (RR = 4.5), and systolic hypotension (RR = 2.6) were associated with an increased risk of encephalopathic syndromes, especially coma. [Pg.2244]

Pepin J, Milord F. The treatment of human African trypanosomiasis. Adv Parasitol 1994 33 1 7. [Pg.2244]

Blum 1, Nkunku S, Burri C. Clinical description of encephalopathic syndromes and risk factors for their occm-rence and outcome during melarsoprol treatment of human African trypanosomiasis. Trop Med Int Health 2001 6(5) 390-400. [Pg.2244]

Ruiz lA, Simarro PP, Josenando T. Control of human African trypanosomiasis in the Ouicama focus, Angola. Bull World Health Organ 2002 80(9) 738 5. [Pg.2244]

Human African Trypanosomiasis Epidemiology and Control E.M. Fevre, K. Picozzi, J. Jannin,... [Pg.407]

Drugs for the treatment of human African trypanosomiasis are also inadequate. The diamidine pentamidine and the sulphonated naphthylamine suramin have been used for over 50 years, require parenteral administration and are only effective against the early haemolymphatic stage of the disease. The only drug currently available for the treatment of the late stage CNS infection is the... [Pg.786]

Fairlamb AH. Chemotherapy of human African trypanosomiasis Current and future prospects. Trends Parasitol 2003 19(ll) 488-94. [Pg.60]

Burri C. Chemotherapy against human African trypanosomiasis is there a road to success Parasitology 2010 137 1987-94. [Pg.498]

The Drugs for Neglected Diseases initiative (DNDi) is a collaborative, nonprofit R D organization aiming to deliver new treatments for neglected diseases. In particular, these include sleeping sickness (human African trypanosomiasis), Chagas disease, leishmaniasis, filarial parasitic-worm infections, and pediatric HIV. The primary aim is to deliver a total of 11-13 new treatments by 2018. [Pg.320]

Noe, R.A., Bowling, T.S., Mercer, L.T. et al. (2011) SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human african trypanosomiasis. PLoS Neglected Tropical Diseases, 5, ell51. [Pg.327]

Keywords Chaga s disease Human African trypanosomiasis (HAT)... [Pg.315]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...